EGFR and hepatocellular carcinoma: In HCC, the EGFR/PI3K/AKT/mTOR pathway is abnormally activated in approximately 50% of cases, and this dysregulated activation is involved in various cellular processes, including cell proliferation, tumor cell differentiation, autophagy, metabolism, and the epithelial–mesenchymal transition (EMT) [14].